Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current opinion in hematology

• Publication date

  2003-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00062752-200301000-00007PMID 12483110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2

  2002cited by this paper
• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  2002cited by this paper
• The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

  2002cited by this paper
• Smart drugs: tyrosine kinase inhibitors in cancer therapy.

  2002cited by this paper
• A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

  2002cited by this paper
• The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

  2002cited by this paper
• Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

  2002cited by this paper
• CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

  2002cited by this paper
• Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

  2002cited by this paper
• Functional Cooperation among Ras, STAT5, and Phosphatidylinositol 3-Kinase Is Required for Full Oncogenic Activities of BCR/ABL in K562 Cells*

  2002cited by this paper
• Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis

  2002cited by this paper
• BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Critical role for Gab2 in transformation by BCR/ABL.

  2002cited by this paper
• Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells

  2002cited by this paper
• Recent advancements in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412

  2002cited by this paper
• Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

  2002cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.

  2002cited by this paper
• Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.

  2002cited by this paper
• Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.

  2002cited by this paper
• Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta

  2002cited by this paper
• BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• a 1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI 571

  2001cited by this paper
• Post-transcriptional gene silencing by double-stranded RNA

  2001cited by this paper
• Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

  2001cited by this paper
• Chromosomal stability and the DNA double-stranded break connection

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability.

  2001cited by this paper
• Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

  2001cited by this paper
• Telomere dysfunction increases mutation rate and genomic instability.

  2001cited by this paper
• Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.

  2001cited by this paper
• Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.

  2001cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.

  2001cited by this paper
• Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.

  2001cited by this paper
• BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

  2001cited by this paper
• In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

  2001cited by this paper
• FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy

  2001cited by this paper
• BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression*

  2001cited by this paper
• Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

  2001cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• Bcr-Abl inhibition as a modality of CML therapeutics.

  2001cited by this paper
• Roots of clinical resistance to STI-571 cancer therapy.

  2001cited by this paper
• Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia

  2001cited by this paper
• H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).

  2001cited by this paper
• Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

  2001cited by this paper
• TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome.

  2001cited by this paper
• Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase

  2001cited by this paper
• DNA-PKcs is critical for telomere capping

  2001cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• BCR/ABL inhibition by an escort/phosphatase fusion protein.

  2000cited by this paper
• Cell‐penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

  2000cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

  2000cited by this paper
• c‐Kit and c‐kit mutations in mastocytosis and other hematological diseases

  2000cited by this paper
• Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).

  2000cited by this paper
• Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.

  2000cited by this paper
• Role of 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI 571

  2000cited by this paper
• Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.

  2000cited by this paper
• Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1

  2000cited by this paper
• The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.

  2000cited by this paper
• Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

  2000cited by this paper
• Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

  2000cited by this paper
• Prognostic Implication of FLT 3 and N-RAS Gene Mutations in Acute Myeloid Leukemia

  1999cited by this paper
• Oligonucleotide therapeutics for hematologic disorders.

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper
• Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis

  1996cited by this paper

• Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome

  2012cites this paper
• Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance

  2010cites this paper
• Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay.

  2010cites this paper
• Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients

  2009cites this paper
• Hypereosinophilic syndrome and molecularly targeted therapy

  2007cites this paper
• Gene expression pattern of signal transduction in chronic myeloid leukemia

  2006cites this paper
• The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1

  2005cites this paper
• A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

  2005cites this paper
• Imatinib mesylate—gold standards and silver linings

  2004cites this paper
• The FIP1L1-PDGFR&agr; kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia

  2004cites this paper
• FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.

  2004cites this paper
• Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.

  2003cites this paper